NG,NG-dimethyl-L-Arginine (hydrochloride)
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
NG,NG-dimethyl-L-Arginine is an endogenous nitric oxide synthase inhibitor.
Nitric oxide (NO) that is synthesised from L-arginine contributes to the regulation of blood pressure and to host defence.
In vitro: NG,NG-dimethyl-L-Arginine (ADMA) was found to be able to inhibit macrophage and vascular NO synthase. When added to a cytosolic preparation of macrophage NO synthase, ADMA could cause dose-dependent inhibition of NO formation. In the presence of added arginine, ADMA could inhibited NO synthesis and the inhibitory effects of ADMA were prevented by addition of L-arginine so that the rate of NO synthesis did not significantly differ from control values [1].
In vivo: Animal study showed that the injection of 1-30 mg/kg ADMA into 3 anaesthetised guineapigs could cause dose-dependent increases in mean arterial blood pressure. Moreover, during continuous infusion of ADMA, which caused plasma ADMA concentrations to rise approximately 9-fold, the systolic blood pressure was raised by nearly 15 % [1].
Clinical trial: Local infusion of ADMA into the brachial artery of healthy volunteers caused a dose-dependent fall in forearm blood-flow. Infusion of ADMA for 5 min resulted in a fall in forearm blood-flow in 5 subjects, and the effects of this ADMA dose were significantly attenuated by infusion of L-arginine [1].
Reference:
[1] Vallance, P. ,Leone, A.,Calver, A., et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339, 572-575 (1992).
- 1. Ziang Xie, Lei Hou, et al. "Mechanical force promotes dimethylarginine dimethylaminohydrolase 1-mediated hydrolysis of the metabolite asymmetric dimethylarginine to enhance bone formation." Nat Commun. 2022 Jan 10;13(1):50. PMID:35013196
- 2. Ming Wu, Meijie Yuan, et al. "Renal asymmetric dimethylarginine inhibits fibrosis." FEBS Open Bio. 2020 Oct;10(10):2003-2009. PMID:32794631
- 3. Wu M, Lin P, et al. "Reduced asymmetric dimethylarginine accumulation through inhibition of the type I protein arginine methyltransferases promotes renal fibrosis in obstructed kidneys." FASEB J. 2019 Jun;33(6):6948-6956. PMID:30840839
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 275.2 |
Cas No. | 220805-22-1 |
Formula | C8H18N4O2·2HCl |
Synonyms | ADMA |
Solubility | ≥11.5 mg/mL in EtOH; ≥14.9 mg/mL in H2O; ≥7.96 mg/mL in DMSO |
Chemical Name | N5-[(dimethylamino)iminomethyl]-L-ornithine, dihydrochloride |
SDF | Download SDF |
Canonical SMILES | OC(=O)[C@@H](N)CCCNC(=N)N(C)C |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |